Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
Main Author: | Weixian Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Thoracic Cancer |
Online Access: | https://doi.org/10.1111/1759-7714.13233 |
Similar Items
-
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01) -
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01) -
Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques
in the Lung Cancer Immunotherapy
by: Wenjia SUN, et al.
Published: (2021-01-01) -
Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01) -
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
by: Naoya Maekawa, et al.
Published: (2021-02-01)